Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 17/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13739613 | 0.92 | NAMPT (0.62) | NAMPTCYP2C9 | |
| SCHEMBL13739405 | 0.91 | NAMPT (0.58) | NAMPTCYP2C9 | |
| SCHEMBL13740809 | 0.89 | NAMPT (0.60) | NAMPTCYP2C9 | |
| SCHEMBL13740492 | 0.89 | NAMPT (0.65) | NAMPTCYP2C9 | |
| SCHEMBL13739924 | 0.89 | NAMPT (0.58) | NAMPTCYP2C9 | |
| SCHEMBL13738960 | 0.88 | NAMPT (0.59) | NAMPTCYP2C9 | |
| SCHEMBL13741063 | 0.88 | NAMPT (0.63) | NAMPTCYP2C9 | |
| SCHEMBL29944175 | 0.88 | NAMPT (0.63) | NAMPTCYP2C9 | |
| SCHEMBL13740735 | 0.87 | NAMPT (0.58) | NAMPTCYP2C9 | |
| SCHEMBL13739163 | 0.87 | NAMPT (0.56) | NAMPTCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170137441-A1 | Piperidine Derivatives And Compositions For the Inhibition Of Nicotinamide Phosphoribosyltransferase (NAMPT) | VALO EARLY DISCOVERY, INC. | 2017-05-18 | — | — | US | claimed |
| US-9555039-B2 | Piperidine derivatives and compositions for the inhibition of nicotinamide phosphoribosyltransferase (NAMPT) | FORMA TM, LLC. (US) | 2017-01-31 | — | — | US | claimed |
| US-20140248240-A1 | PIPERIDINE DERIVATIVES AND COMPOSITIONS FOR THE INHIBITION OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) | VALO HEALTH, INC. | 2014-09-04 | — | — | US | claimed |
| WO-2012154194-A1 | PIPERIDINE DERIVATIVES AND COMPOSITIONS FOR THE INHIBITION OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) | FORMA TM, LLC (US) | 2012-11-15 | — | — | WO | claimed |
| US-20190031686-A1 | PIPERIDINE DERIVATIVES AND COMPOSITIONS FOR THE INHIBITION OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) | VALO EARLY DISCOVERY, INC. | 2019-01-31 | — | — | US | disclosed |
| US-20170137441-A1 | Piperidine Derivatives And Compositions For the Inhibition Of Nicotinamide Phosphoribosyltransferase (NAMPT) | VALO EARLY DISCOVERY, INC. | 2017-05-18 | — | — | US | disclosed |
| US-20170137441-A1 | Piperidine Derivatives And Compositions For the Inhibition Of Nicotinamide Phosphoribosyltransferase (NAMPT) | VALO EARLY DISCOVERY, INC. | 2017-05-18 | — | — | US | disclosed |
| US-9555039-B2 | Piperidine derivatives and compositions for the inhibition of nicotinamide phosphoribosyltransferase (NAMPT) | FORMA TM, LLC. (US) | 2017-01-31 | — | — | US | disclosed |
| US-20140248240-A1 | PIPERIDINE DERIVATIVES AND COMPOSITIONS FOR THE INHIBITION OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) | VALO HEALTH, INC. | 2014-09-04 | — | — | US | disclosed |
| WO-2013170191-A1 | METHODS OF USING ANTAGONISTS OF NAD BIOSYNTHESIS FROM NICOTINAMIDE | GENENTECH, INC. (US) | 2013-11-14 | — | — | WO | disclosed |
| WO-2012154194-A1 | PIPERIDINE DERIVATIVES AND COMPOSITIONS FOR THE INHIBITION OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) | FORMA TM, LLC (US) | 2012-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190031686-A1 | PIPERIDINE DERIVATIVES AND COMPOSITIONS FOR THE INHIBITION OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) | NAMPT, NAPRT, NNMT | NAMPT 1/4885CYP2C9 1616/4885DRD2 1549/4885 |
| US-20170137441-A1 | Piperidine Derivatives And Compositions For the Inhibition Of Nicotinamide Phosphoribosyltransferase (NAMPT) | NAMPT, NAPRT, NNMT | NAMPT 1/4885CYP2C9 1616/4885DRD2 1549/4885 |
| US-20140248240-A1 | PIPERIDINE DERIVATIVES AND COMPOSITIONS FOR THE INHIBITION OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) | NAMPT, NAPRT, NNMT | NAMPT 1/4885CYP2C9 1195/4885DRD2 1702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.